Cosmo Pharmaceuticals N.V., headquartered in Dublin and recognized for its AI-powered healthcare and specialty pharma solutions, announced two strategic sustainability milestones today. The company's S&P Global Corporate Sustainability Assessment has been advanced to the 67th percentile, up sharply from last year's 55th percentile, a move that solidifies Cosmo's position as one of the top ESG performers in the pharmaceutical technology sector. This reflects measurable and robust improvement in governance, environmental stewardship, and social responsibility, reinforcing Cosmo's ongoing integration of sustainability throughout its operations and leadership practices.

In parallel, Cosmo SpA, the company’s Italian manufacturing subsidiary, received the EcoVadis Bronze Medal for sustainable manufacturing practices. With an overall score of 64 out of 100, the facility ranked higher than 71% of all entities assessed by EcoVadis. This distinction recognizes Cosmo's comprehensive efforts in environmental management, ethical conduct, and the continual development of a sustainable, transparent, and responsible supply chain. These achievements follow Cosmo’s strategic decision to partner with EcoVadis to systemically evaluate all suppliers for compliance with rigorous environmental, social, ethical, and procurement standards, leading to improved supply chain risk management and deeper stakeholder engagement throughout its European operations.

According to Niall Donnelly, Cosmo’s EVP Corporate Governance & Chief Sustainability Officer, these advances demonstrate the company's unwavering commitment to embedding ESG priorities "into everything we do, from responsible sourcing to transparent disclosure." Cosmo is purposefully aligning its ESG management framework with leading global standards, specifically the Task Force on Climate-Related Financial Disclosures (TCFD) and the Corporate Sustainability Reporting Directive (CSRD), to improve regulatory compliance, investor confidence, and operational resilience.

Cosmo's ESG initiatives coincide with its continued growth in contract development and manufacturing (CDMO) services, positioning the company as a preferred partner for global pharmaceutical and MedTech brands seeking advanced, sustainable production solutions. The Italian plant’s high sustainability rating translates to enhanced value for pharma procurement and operations leaders considering ESG criteria in supplier selection. The focus on responsible sourcing is expected to further mitigate supply chain risks, supporting business continuity and regulatory compliance requirements, especially as European regulations on carbon disclosure, supplier due diligence, and green manufacturing intensify.

The company announced that its next formal ESG Report, compliant with TCFD and CSRD, will be released in March 2026, offering transparent disclosures for business partners, investors, and regulatory stakeholders. Cosmo’s sustained investment in sustainability is strategically designed to support long-term supplier relationships, minimize operational risks, and meet the growing ESG expectations facing pharmaceutical manufacturers and their value chain partners across Europe.

Founded in 1997, Cosmo Pharmaceuticals has expanded its expertise from MedTech AI to dermatology, gastrointestinal diseases, and advanced CDMO services. The company's technologies serve leading pharmaceutical and MedTech organizations worldwide, with operations spanning Ireland, Italy, and the US. As regulatory and investor scrutiny on ESG intensifies across Europe, Cosmo’s proactive stance in supplier sustainability oversight and manufacturing transparency sets an evolving benchmark for the region’s pharma manufacturing segment.

For Europe-based pharmaceutical executives, procurement professionals, and R&D/manufacturing leaders, today’s ESG advancements by Cosmo Pharmaceuticals reflect a broader industry trend toward rigorous third-party sustainability validation and increased supplier assessment. The recognition from both S&P Global and EcoVadis is likely to impact future business partnerships, procurement decisions, and compliance strategies for companies prioritizing ESG in their operations and supply chains.